Colorectal cancer: Review of signaling pathways and associated therapeutic strategies

被引：11

作者：

Leiphrakpam, Premila D. ^{[1
,2
]}

Rajappa, Senthil J. ^{[3
]}

Krishnan, Mridula ^{[4
]}

Batra, Rishi ^{[5
]}

Murthy, Shilpa S. ^{[6
]}

Are, Chandrakanth ^{[1
,2
,7
]}

机构：

[1] Univ Nebraska Med Ctr, Coll Med, Grad Med Educ, Omaha, NE USA

[2] Univ Nebraska Med Ctr, Coll Med, Dept Surg, Div Surg Oncol, Omaha, NE USA

[3] Basavatarakam Indo Amer Canc Hosp, Med Oncol, Hyderabad, Telangana, India

[4] Univ Nebraska Med Ctr, Coll Med, Dept Internal Med, Div Oncol & Hematol, Omaha, NE USA

[5] Univ Nebraska Med Ctr, Coll Med, Dept Surg, Div Gen Surg, Omaha, NE USA

[6] Mem Sloan Kettering Canc Ctr, Div Surg Oncol, Global Canc Dispar Initiat, New York, NY USA

[7] Univ Nebraska Med Ctr, Coll Med, Dept Surg, Div Surg Oncol, Omaha, NE 68198 USA

来源：

JOURNAL OF SURGICAL ONCOLOGY | 2023年 / 127卷 / 08期

关键词：

biomarkers; colorectal cancer; targeted therapy; RANDOMIZED PHASE-III; FOLFIRI PLUS BEVACIZUMAB; MOLECULAR SUBGROUP ANALYSES; FACTOR-BETA RECEPTOR; KRAS WILD-TYPE; OPEN-LABEL; 1ST-LINE TREATMENT; FOLFOXIRI PLUS; DOUBLE-BLIND; MAINTENANCE TREATMENT;

D O I：

10.1002/jso.27295

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Tumor profiling and targeted therapy revolutionized the treatment strategies of metastatic colorectal cancer (mCRC) in the last decade. The heterogeneity of CRC tumors plays a critical role in the development of treatment resistance, which underscores the need to understand the molecular mechanism involved in CRC to develop novel targeted therapeutic strategies. This review provides an overview of the signaling pathways driving CRC, the existing targeted agents, their limitations, and future trends.

引用

页码：1277 / 1295

页数：19

共 98 条

[81] Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group [J].

Simkens, Lieke H. J. ;

van Tinteren, Harm ;

May, Anne ;

ten Tije, Albert J. ;

Creemers, Geert-Jan M. ;

Loosveld, Olaf J. L. ;

de Jongh, Felix E. ;

Erdkamp, Frans L. G. ;

Erjavec, Zoran ;

van der Torren, Adelheid M. E. ;

Tol, Jolien ;

Braun, Hans J. J. ;

Nieboer, Peter ;

van der Hoeven, Jacobus J. M. ;

Haasjes, Janny G. ;

Jansen, Rob L. H. ;

Wals, Jaap ;

Cats, Annemieke ;

Derleyn, Veerle A. ;

Honkoop, Aafk E. H. ;

Mol, Linda ;

Punt, Cornelis J. A. ;

Koopman, Miriam .

LANCET, 2015, 385 (9980) :1843-1852

[82] Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives [J].

Spano, JP ;

Fagard, R ;

Soria, JC ;

Rixe, O ;

Khayat, D ;

Milano, G .

ANNALS OF ONCOLOGY, 2005, 16 (02) :189-194

[83] Randomized study to investigate FOLFOXIRI plus either bevacizumab or cetuximab as first-line treatment of BRAF V600E-mutant mCRC: The phase-II FIRE-4.5 study (AIO KRK-0116). [J].

Stintzing, Sebastian ;

Heinrich, Kathrin ;

Tougeron, David ;

Modest, Dominik Paul ;

Schwaner, Ingo ;

Euker, Jan ;

Pihusch, Rudolf ;

Stauch, Martina ;

Kaiser, Florian ;

Kahl, Christoph ;

Karthaus, Meinolf ;

Mueller, Christian ;

Burkart, Christof ;

Reinacher-Schick, Anke C. ;

Kasper, Stefan ;

von Weikersthal, Ludwig Fischer ;

Krammer-Steiner, Beate ;

Prager, Gerald W. ;

Taieb, Julien ;

Heinemann, Volker .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

[84] Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study [J].

Tabernero, Josep ;

Grothey, Axel ;

Van Cutsem, Eric ;

Yaeger, Rona ;

Wasan, Harpreet ;

Yoshino, Takayuki ;

Desai, Jayesh ;

Ciardiello, Fortunato ;

Loupakis, Fotios ;

Hong, Yong Sang ;

Steeghs, Neeltje ;

Guren, Tormod Kyrre ;

Arkenau, Hendrik-Tobias ;

Garcia-Alfonso, Pilar ;

Elez, Elena ;

Gollerkeri, Ashwin ;

Maharry, Kati ;

Christy-Bittel, Janna ;

Kopetz, Scott .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (04) :273-+

[85] Phase 2 results: Encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC). [J].

Tabernero, Josep ;

Van Geel, Robin ;

Guren, Tormod Kyrre ;

Yaeger, Rona D. ;

Spreafico, Anna ;

Faris, Jason Edward ;

Yoshino, Takayuki ;

Yamada, Yasuhide ;

Kim, Tae Won ;

Bendell, Johanna C. ;

Schuler, Martin H. ;

Lenz, Heinz-Josef ;

Eskens, Ferry ;

Desal, Jayesh ;

Hochster, Howard S. ;

Avsar, Emin ;

Demuth, Tim ;

Sandor, Victor ;

Elez, Elena ;

Schellens, Jan H. M. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

[86] Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study [J].

Tabernero, Josep ;

Yoshino, Takayuki ;

Cohn, Allen Lee ;

Obermannova, Radka ;

Bodoky, Gyorgy ;

Garcia-Carbonero, Rocio ;

Ciuleanu, Tudor-Eliade ;

Portnoy, David C. ;

Van Cutsem, Eric ;

Grothey, Axel ;

Prausova, Jana ;

Garcia-Alfonso, Pilar ;

Yamazaki, Kentaro ;

Clingan, Philip R. ;

Lonardi, Sara ;

Kim, Tae Won ;

Simms, Lorinda ;

Chang, Shao-Chun ;

Nasroulah, Federico .

LANCET ONCOLOGY, 2015, 16 (05) :499-508

[87] Bevacizumab Plus mFOLFOX6 Versus mFOLFOX6 Alone as First-Line Treatment for RAS Mutant Unresectable Colorectal Liver-Limited Metastases: The BECOME Randomized Controlled Trial [J].

Tang, Wentao ;

Ren, Li ;

Liu, Tianshu ;

Ye, Qinghai ;

Wei, Ye ;

He, Guodong ;

Lin, Qi ;

Wang, Xiaoying ;

Wang, Mingliang ;

Liang, Fei ;

Cui, Yuehong ;

Xu, Jianmin .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (27) :3175-+

[88] Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial [J].

Tournigand, Christophe ;

Chibaudel, Benoist ;

Samson, Benoit ;

Scheithauer, Werner ;

Vernerey, Dewi ;

Mesange, Paul ;

Lledo, Gerard ;

Viret, Frederic ;

Ramee, Jean-Francois ;

Tubiana-Mathieu, Nicole ;

Dauba, Jerome ;

Dupuis, Olivier ;

Rinaldi, Yves ;

Mabro, May ;

Aucoin, Nathalie ;

Latreille, Jean ;

Bonnetain, Franck ;

Louvet, Christophe ;

Larsen, Annette K. ;

Andre, Thierry ;

de Gramont, Aimery .

LANCET ONCOLOGY, 2015, 16 (15) :1493-1505

[89]

Van Cutsem E., 2014, Ann Oncol, V25

[90] Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen [J].

Van Cutsem, Eric ;

Tabernero, Josep ;

Lakomy, Radek ;

Prenen, Hans ;

Prausova, Jana ;

Macarulla, Teresa ;

Ruff, Paul ;

van Hazel, Guy A. ;

Moiseyenko, Vladimir ;

Ferry, David ;

McKendrick, Joe ;

Polikoff, Jonathan ;

Tellier, Alexia ;

Castan, Remi ;

Allegra, Carmen .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (28) :3499-3506

← 1 2 3 4 5 6 7 8 9 10 →